WuXi PharmaTech (NYSE: WX) Mourns the Tragic Loss of Its Independent Director Shawn Wang
Dec 30, 2007
December 30, 2007 - Shanghai, China - WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services, sadly announced today one of its independent directors, Mr. Shawn Wang, Chief Financial Officer of Baidu, passed away in an accident during his vacation on December 27, 2007.
Mr. Shawn Wang was appointed as an independent director on WuXi PharmaTech's Board of Directors in July, 2007 when the company was preparing its public listing on the New York Stock Exchange. During his brief tenure and as the Chairman of the Audit Committee, Shawn advised the company's management in particular areas of financial reporting, Sarbanes-Oxley Act compliance and investor relations.
"We are all deeply saddened by the tragic and untimely loss of Shawn. He was not only a remarkable leader but also a very close personal friend of mine," said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech." We are honored and grateful for having known and worked with Shawn. I will miss him very much and my thoughts and prayers go out to Shawn's family."
About WuXi PharmaTech (Cayman) Inc.
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: www.wuxiapptec.com.